Candidemia in the intensive care unit: analysis of direct treatment costs and clinical outcome in patients treated with echinocandins or fluconazole

摘要: Direct treatment costs caused by candidemia in German intensive care unit (ICU) patients are currently unknown. We analyzed and the impact of antifungal drug choice. Comprehensive data who had at least one episode while staying ICU between 01/2005 12/2010 were documented a database using technology Cologne Cohort Neutropenic Patients (CoCoNut). A detailed analysis all disease-associated was performed. treated with echinocandins (i.e., anidulafungin, caspofungin, micafungin) or fluconazole separately compared. Forty-one 64 received fluconazole, respectively. The mean Acute Physiology Chronic Health Evaluation (APACHE) IV score 114 (95 % confidence interval [CI]: 106–122) vs. 95 CI: 90–101, p = <0.001). Twenty-three (56 %) 33 (52 %, 0.448) survived hospitalization, 17 (41 22 (34 0.574) year after diagnosis. In echinocandin groups, per patient €20,338 €12,893–27,883) €11,932 €8,016–15,849, 0.110), total direct €37,995 €26,614–€49,376) €22,305 €16,817–€27,793, 0.012), resulting daily €1,158 €1,036–€1,280) €927 €828–€1,026, 0.001). Our health economic shows high ICU. Sicker prolonged hospitalization more likely to receive echinocandins, leading higher costs. Outcomes comparable those achieved less sick fluconazole.